Defence Therapeutics Inc. (DTC.CN)
| Previous Close | 2.0000 |
| Open | 0.0000 |
| Bid | 2.0500 x N/A |
| Ask | 2.1000 x N/A |
| Day's Range | 2.0000 - 2.0000 |
| 52 Week Range | 2.0000 - 8.1500 |
| Volume | |
| Avg. Volume | 8,016 |
| Market Cap | 71.929M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1430 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.02 |
- Newsfile
Defence's Accum(TM) with Antibody Drug Conjugates (ADC) in Development Against Cancer
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defence's AccumTM, including key in vivo studies with worldwide collaborators. The world-renowned Curie Institute, one of Defence's collabor
- Newsfile
Defence Reports Effective Control of Cervical Cancer Growth in Response to Its AccuVAC-PT007 Therapeutic Vaccination
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report potent pre-clinical results on the use of its AccumTM-linked protein vaccine, AccuVAC-PT007, against cervical cancer. Cervical cancer is a type of cancer affecting the cervix. Various strains
- Newsfile
RETRANSMISSION: Defence's Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer
The Company is issuing a clarification news release at the request of IIROC.Vancouver, British Columbia--(Newsfile Corp. - May 18, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focused on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to prote
